Impact of initial serum ferritin on early post-HSCT complications: a single-center study

Mostafa Shaheen,1,2 Maria O. Ivanova,1 Ivan S. Moiseev,1 Sergey V. Bondarchuk,3 Boris V. Afanasyev1
1. R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, The First St. Petersburg Pavlov State Medical University, St. Petersburg, Russia
2. Hematology and Bone Marrow Transplantation Department, Tishreen Hospital, Damascus, Syria
3. Department of Hematology, Faculty Therapy, S.M.Kirov Military Medical Academy, St. Petersburg, Russia

Resume

Introduction
Iron overload (IO) is an important issue when treating patients who undergo hematopoietic stem cell transplantation (HCT). Elevated pre-transplant serum ferritin levels have been associated with increased morbidity and mortality after allogeneic HCT.

Patients and Methods
In the single-center study, we have reviewed medical records of ninety-one consecutive patients (42 males and 49 females), with a median age at HCT of 31.6 years (range, 5 to 60), who underwent allo-HCT with unmanipulated grafts between Jan 2013 and Dec 2014.

Results
The median pre-HCT serum ferritin concentration was 765.35 (range, 12.1-4247) ng/mL for the total group. Fifty-three patients (58.24%) had initial serum ferritin of >500 ng/mL, and were assigned to the high-ferritin group. Increased pre-transplant ferritin concentrations were significantly associated with toxic or infectious complications of HCT, i.e., number of febrile neutropenic episodes (P=0.005), number of bacterial infection episodes (P=0.009), pneumonias (P=0.04), and demand for multiple RBC transfusions (P=0.04) within 100 days post-HCT. The significant association was found between pre-HCT ferritin concentrations (>773 ng/mL) and overall survival (P=0.04), disease-free survival (P=0.019), and mortality (P=0.02) among the groups. No significant relationships were observed between the initial ferritin levels and incidence of mucositis, or graft-versus-host disease (P>0.05).

Conclusion
Measurement of serum ferritin, as a surrogate laboratory marker for IO, is quite practical for many hematological clinics. In the present study it was shown that the baseline increase of serum ferritin contents, is associated with higher risk of febrile episodes, infectious conditions, and slower recovery of myeloid cells, thus being of certain predictive value. Of special interest is an association between the pre-transplant ferritin levels and increasing demand for RBC transfusions after allo-HCT.

Keywords
hematopoietic stem cell transplantation, allogeneic, iron overload, serum ferritin, complications, early infectious, survival.
**Introduction**

Iron takes part in several metabolic processes, including DNA synthesis, oxygen and electron transport. Most of the iron in human body is distributed within hemoglobin (65%; 2300 mg). Ca. 10% is present in muscles and other tissues, e.g., liver (200 mg), macrophages (500 mg), and bone marrow (150 mg) [23].

Ferritin is the main iron storage molecule. It makes ferrous ions available for critical cellular processes, while protecting lipids, DNA and proteins from potentially toxic effects of free iron. Increased iron load may, however, saturate the available transferring pool and lead to excessive levels of non-transferrin-bound iron which may be subsequently captured and stored either within ferritin, or hemosiderin molecules [14].

Therefore, serum ferritin is considered a simple and widely used surrogate marker for IO. However, many confounding factors, particularly in HCT recipients, may result in potential IO overestimation. E.g., inflammation, infections, liver damage and GvHD may also lead to elevated serum ferritin levels [21]. Repeated serum ferritin measurements can reveal potential causes and help to establish a general pattern of the iron overload over time.

On the basis of serum ferritin levels, the diagnosis of iron overload has been reported in up to 88% of long term HSCT survivors. When liver iron content is assessed by MRI technique, the prevalence of iron excess is reported to be 32% in allo-HCT recipients who survived 1 year or more following HCT [19].

The adverse impact of IO on the HSCT outcome was first demonstrated in thalassemia patients [10]. In MDS patients, a transfusion dependency was considered a prognostic factor in WHO classification–based Prognostic Scoring System (WPSS) and independently associated with reduced OS and increased NRM [1].

Different workers have presumed an iron overload to be a risk factor for clinical complications in HCT recipients, including higher occurrence of mucositis [3], increased infection rates [2, 7, 12, 15, 25], liver functions abnormality [9], GvHD severity [18, 6], and non-relapse mortality [4].

Hence, the aim of our single-center study was to confirm previous reports and assess a predictive value of the baseline ferritin levels for different early complications of HSCT procedure.

**Patients and methods**

We have retrospectively evaluated a group of ninety-one consecutive patients undergoing unmanipulated allo-HCT in R.M. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation at the St. Petersburg Pavlov State Medical University, St. Petersburg, between 01/01/2013 and 03/09/2014. The inclusion criteria were as follows: (1) First allo-HCT from HLA-compatible related, unrelated or haplo-identical donors; (2) Primary malignant, or non-malignant disease; (3) Age: 5 to 60 years; (4) Karnofsky performance status ≥70 %.

The cohort included 42 men and 49 women with a median age at transplantation of 31.6 (range, 5 to 60) years. Underlying diseases were acute myeloid leukemia (n=68), myelodysplastic syndrome (n=10), myeloproliferative neoplasms (n=4; Primary myelofibrosis =3, Chronic myelomonocytic leukemia=1), bone marrow failure (n=7; Aplastic anemia=6, Fanconi anemia=1) and B-thalassemia major (n=2). Stem cell transplants were from (HLA)-identical siblings (n=16), haplo-identical (n=6), or unrelated volunteer donors; (n=69).

The conditioning regimens were myeloablative (MAC) in 26 patients, or reduced-intensity (RIC) in the rest of this group.

The follow-up period was 100 days after allo-HCT. Baseline characteristics of the patients are given in Table 1. We evaluated the effects of high pre-allo-HCT serum ferritin on early toxic, infectious and other complications, as well as early transplant outcomes.

The study was approved by the Institutional Review Board at the First St.Petersburg State Pavlov Medical University. Each patient has given an informed consent for the use of personal data.

**Table 1. Patients baseline characteristics**

<table>
<thead>
<tr>
<th>Total number of patients</th>
<th>91</th>
<th>%</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>42 (46%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>49 (54%)</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>median age</td>
<td>31.6</td>
<td>(5-60) ys</td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AML</td>
<td>68 (75%)</td>
<td>74.70</td>
<td></td>
</tr>
<tr>
<td>MDS</td>
<td>10 (11%)</td>
<td>10.90</td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>n (%)</td>
<td>10^6</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>--------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>PMF</td>
<td>3 (3%)</td>
<td>3.20</td>
<td></td>
</tr>
<tr>
<td>AA</td>
<td>6 (6.5%)</td>
<td>6.50</td>
<td></td>
</tr>
<tr>
<td>B-Thalassemia major</td>
<td>2 (2%)</td>
<td>2.10</td>
<td></td>
</tr>
<tr>
<td>Fanconi anemia</td>
<td>1 (%)</td>
<td>1.10</td>
<td></td>
</tr>
<tr>
<td>Chronic myelomonocytic leukemia</td>
<td>1 (%)</td>
<td>1.10</td>
<td></td>
</tr>
<tr>
<td>Status of malignant disease (n=82)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Complete remission (CR)</td>
<td>53</td>
<td>64.60</td>
<td></td>
</tr>
<tr>
<td>non-CR</td>
<td>29</td>
<td>33.40</td>
<td></td>
</tr>
<tr>
<td>Type of allo-HCT MRD</td>
<td>16</td>
<td>17.50</td>
<td></td>
</tr>
<tr>
<td>MUD</td>
<td>58</td>
<td>63.70</td>
<td></td>
</tr>
<tr>
<td>haplo</td>
<td>6</td>
<td>6.60</td>
<td></td>
</tr>
<tr>
<td>MMUD</td>
<td>11</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Conditioning regimen MAC</td>
<td>26</td>
<td>28.60</td>
<td></td>
</tr>
<tr>
<td>RIC</td>
<td>65</td>
<td>71.40</td>
<td></td>
</tr>
<tr>
<td>Source of stem cells BM</td>
<td>37</td>
<td>40.60</td>
<td></td>
</tr>
<tr>
<td>PBSC</td>
<td>52</td>
<td>57.10</td>
<td></td>
</tr>
<tr>
<td>PBSC+BM</td>
<td>2</td>
<td>2.20</td>
<td></td>
</tr>
<tr>
<td>median CD34+ / ×10^6</td>
<td>5.07</td>
<td>(1.3-14.1)</td>
<td></td>
</tr>
<tr>
<td>median CD3+ / ×10^7</td>
<td>13</td>
<td>(12-39.5)</td>
<td></td>
</tr>
<tr>
<td>Donor M / F</td>
<td>59/31 1/2</td>
<td>64.8 /31.2</td>
<td></td>
</tr>
<tr>
<td>median donor age</td>
<td>32.3</td>
<td>(3.9-56)</td>
<td></td>
</tr>
<tr>
<td>RBC counts pre-transplant, M±m</td>
<td>3.3±0.07 (0.7)</td>
<td>(1.6-5.0)</td>
<td></td>
</tr>
<tr>
<td>Median Hb concentration g/l</td>
<td>106.3±2.5 (23.6)</td>
<td>(50-155)</td>
<td></td>
</tr>
<tr>
<td>Mean RBC volume, f/L</td>
<td>97.7±0.8 (7.3)</td>
<td>(79.7-117.4)</td>
<td></td>
</tr>
<tr>
<td>Mean ferritin level pre-allo HSCT ng/ml. normal (11-307)</td>
<td>765.35±70.9 (676.3)</td>
<td>(12.1-4247)</td>
<td></td>
</tr>
<tr>
<td>Patient erythrocyte antigens:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>42.9% (39/91)</td>
<td>28.6 (26/91)</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donor erythrocyte antigens</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>42.9 (39/91)</td>
<td>16.5 (15/91)</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Major RBC mismatch</td>
<td>14.3 (13/91)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minor RBC mismatch</td>
<td>23.1 (21/91)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Matched related donor, 2 Matched unrelated donor, 3 Mismatched unrelated donor, 4 Myeloablative conditioning regimen, 5 Reduced intensity conditioning regimen,
The study cohort was divided into 2 groups, those with high versus low ferritin concentration (resp. HF and LF groups), on the basis of a 500-ng/mL threshold for increased ferritin concentration. Mucositis was graded on a scale of 0 to 4, according to Common Toxicity Criteria, version 4, from the National Cancer Institute. The International EORTC/MSG Consensus on opportunistic fungal infections (FI) was used for diagnosis of FI [5].

Bacterial infection was defined as recovery of a recognized pathogen from, at least, 2 different sites for 100 Days post-HCT (Data Form 2100). Recovery of neutrophils was blood or urine cultures yielding the same organism. For each patient, the numbers of bacterial, viral and fungal infections were calculated, according to CIBMTR registered when reaching the ANC numbers of >500/μL for the first 3 consecutive days. Acute graft-versus-host disease (aGvHD) was graded according to Gratwwohl criteria [11]. A diagnosis of sinusoidal obstruction syndrome (hepatic veno-occlusive disease) was made on the basis of Seattle criteria, as described by McDonald et al [17].

Continuous variables in the 2 groups were compared by means of the Mann-Whitney test. Categorical variables were compared using the Chi-square test. Overall survival and transplant-related mortality were calculated, using the Kaplan-Meier method. Possible risk factors were tested using the log-rank test. Cutoff levels of ferritin amounts were determined using ROC-analysis. The calculations were made with SPSS 19.

**Results**

Fifty-three (58%) patients with increased serum ferritin concentrations (≥500 ng/mL) were classified as the high-ferritin group (HF), with a median of 1148 ng/mL (range, 650-4247). The rest of patients (n=38, 41.76%) were classified as LF group, and had serum ferritin concentrations (<500 ng/mL) with a median ferritin level of 232 (range, 12.1-466.3 ng/mL).

Active infections within last month prior to HCT were observed only in HF group, including 8 patients with probable invasive pulmonary aspergillosis; 2 cases of soft tissue infection; purulent sinusitis in 2 patients and fever of unknown origin in 2 cases, with a median ferritin level of 1057 ng/mL (606-1875). Hence, fungal infections prevailed among total infections by the date of allo-HCT, and 26.14% of patients in HF group with increased ferritin levels (P= 0.001; [OR], 0.25; 95%(CI), (0.09–0.67)).

Although the percentage of patients with developing bacterial infections was similar in both HF and LF groups (resp., 88.64%, 84.2%), there was a distinct correlation between the increased pre-HCT ferritin and median number of infectious episodes/patient, i.e., 2.7 (0 to 7) in HF group, and 2.0 (0 to 6) in LF sample [P=0.009; (OR), 3.2; 95%(CI), (1.31–7.77)]. Incidence of febrile neutropenia and septicemia post-transplant was more frequent in the HF group (n=20; 30%) vs LF patients (n=8; 13%), at a marginal statistical difference (P>0.05), as shown in Fig. 1.

**Mucositis**

Post-transplant mucositis was observed in seventy patients: 28 (52%) in HF and 19 (50%) in LF group had mucositis grade I-II (P>0.05). 11(21%) in HF group versus 12 (32%) among LF patients had mucositis grade III-IV. No statistical differences were observed between the two groups (P>0.05).

**Febrile neutropenia**

Febrile neutropenia was observed in sixty-seven cases: 42 (79%) in HF vs 23 (60%) in LF group (P > 0.05). Despite the lack of a significant difference between the groups, we revealed a near-linear correlation between the numbers of febrile neutropenia episodes and increase in the mean ferritin levels (Fig. 1). The median for HF group was 1.5 febrile episodes/patient (0 to 6) vs 0.84 (0 to 3) in LF patients [P = 0.005; OR, 4.08; 95% (CI), 1.46–11.42] (Fig.2). Accordingly, the number of patients who required granulocyte colony-stimulating factor (G-CSF) injections in order to boost hematopoiesis and to shorten neutropenic period was: 25 (47%) vs 7 (18%) in the HF and LF groups, respectively [P =0.005; (OR), 0.25 ; 95%(CI), (0.09–0.67)].

**Bacterial infections**

Active infections within last month prior to HCT were observed only in HF group, including 8 patients with probable invasive pulmonary aspergillosis; 2 cases of soft tissue infection; purulent sinusitis in 2 patients and fever of unknown origin in 2 cases, with a median ferritin level of 1057 ng/mL (606-1875). Hence, fungal infections prevailed among total infections by the date of allo-HCT, and 26.14% of patients in HF group with increased ferritin levels (P= 0.001; [OR], 0.25; 95%(CI), (0.09–0.67)).

**Early complications of allogeneic-HCT**

**Mucositis**

Post-transplant mucositis was observed in seventy patients: 28 (52%) in HF and 19 (50%) in LF group had mucositis grade I-II (P>0.05). 11(21%) in HF group versus 12 (32%) among LF patients had mucositis grade III-IV. No statistical differences were observed between the two groups (P>0.05).

**Figure 1. Pre-transplant serum ferritin levels before HSCT in the patients with different numbers of febrile neutropenia episodes posttransplant. Ordinate, mean ferritin levels (ng/mL, M+m). The trend is significant by P=0.005.**

**Figure 2 Association between pre allo-HCT serum ferritin and febrile neutropenic and infectious complications after allo-HCT Abscisse, groups with different post-HCT complications; Ordinate, number of febrile neutropenic episodes (median + range).**

- Febrile neutropenia was observed in sixty-seven cases: 42 (79%) in HF vs 23 (60%) in LF group (P > 0.05). Despite the lack of a significant difference between the groups, we revealed a near-linear correlation between the numbers of febrile neutropenia episodes and increase in the mean ferritin levels (Fig. 1).
- The median for HF group was 1.5 febrile episodes/patient (0 to 6) vs 0.84 (0 to 3) in LF patients [P = 0.005; OR, 4.08; 95% (CI), 1.46–11.42] (Fig.2). Accordingly, the number of patients who required granulocyte colony-stimulating factor (G-CSF) injections in order to boost hematopoiesis and to shorten neutropenic period was: 25 (47%) vs 7 (18%) in the HF and LF groups, respectively [P =0.005; (OR), 0.25 ; 95%(CI), (0.09–0.67)].
- **Mucositis**
- Post-transplant mucositis was observed in seventy patients: 28 (52%) in HF and 19 (50%) in LF group had mucositis grade I-II (P>0.05). 11(21%) in HF group versus 12 (32%) among LF patients had mucositis grade III-IV. No statistical differences were observed between the two groups (P>0.05).
Mixed infections as causes of pneumonia were observed in a large proportion of patients (bacterial, fungal, and viral pathogens): 58.8% and 60% in HF and LF groups, respectively.

**Fungal infections**
In our cohort study, probable or proven fungal infections were observed in 9 patients (17%) from HF group (one patient had two episodes) and 3 patients (7.9%) in LF group, with no statistically significant difference (P > 0.05).

**CMV infection**
During the early period after allo-HCT, CMV reactivation was observed in 38 patients (42% of total), including 23(43%) in HF group, and 15(39%) in LF patients, without statistically significant difference (P>0.05). Likewise, no differences were found for incidence of other viral infections (BK, JC), respectively, 20.8% vs 21% in HF and LF groups. Moreover, we had tested correlation between other clinical features, RBC parameters, and presence of CMV reactivation signs. There were no significant connections found between donor RBC blood antigens, or donor/recipient ABO mismatch, and post-transplant infectious complications. Meanwhile, presence of A antigen (blood group II or IV) in the patients showed a highly significant correlation with CMV reactivation (CMV infection positive in 63% (24/39) of A(+) patients versus 37% (14/51) in the group of A(-) patients (r= 0.342; P<0.01).

**Engraftment time**
The median time of neutrophil reconstitution (≥ 500×10⁹) and platelet engraftment (Plt ≥ 20×10⁹) were, respectively, 22 days (13-43) and 18 days (10-41) in HF group, versus 19.5 days (11-36) and 16.2 days (11-36) in LF group (Fig. 2). A significant HF/LF difference was noted for neutrophil recovery (P=0.047). Interestingly, that was independent of the stem cell dose infused: 5.2 (1.3-14.1)×10⁶ versus 4.84 (1.9-10.1)×10⁶ in HF and LF. Intensity of conditioning regimens did not also affect the engraftment rates in our cohort: MAC/RIC: 26.4/73.6% and 29.5/71.5 % in HF and LF groups, respectively.

**Hepatic veno-occlusive disease**
Only 4 cases were observed in total cohort: 3, in HF and 1, in LF groups. The pre-HCT ferritin levels in these cases were as follows: 4247, 1631, 827.3, 112 ng/mL, and one case with primary myelofibrosis had severe VOD with multiorgan failure, and died on D7+ after transplantation. We did not find any significant statistical difference between the two groups P > 0.05, due to minimal statistics.

**Acute graft-versus-host disease**
Acute GvHD was diagnosed in 24 patients (45.28%), and 18 (47.36%) in HF and LF, respectively. This difference was not statistically significant (P>0.2). A tendency was noted towards higher occurrence of severe aGvHD (Stage III-IV), including hepatic form in HF group (ferritin≥500) (P=0.07). That supports a theory that hepatic iron overload may initiate and worsen hepatic aGvHD.

**Pneumonia**
Increasing incidence of pneumonia was observed, regardless of its causes, in the first group (ferritin ≥500 ng/mL) compared to the second group: 17 cases (30.2%) vs 5 cases (13.15%) in HF and LF, respectively (P=0.04, [OR], 0.33 ; 95%[CI], (0.11–0.99).

**Hemorrhagic cystitis**
Hemorrhagic cystitis was documented in 19 patients (20% of total) with a median incidence on day 32 (range, 1-73). The median ferritin level was 716 ng/ml (12 to 1631), being similar in the HF and LF groups: 11 (20.75%) vs 8 (21%) in HF and LF groups, respectively (P>0.05).

**RBC transfusion requirements**
Number of RBC units transfused was counted for each patient within 100 days post-HCT, and a linear correlation was revealed between the increased pre -HCT ferritin and the number of RBC transfusions. Median number of RBC units/patient was 8.6 units (0 to 36) and 3.1 units (0 to 27) in HF and LF groups P=0.04, [OR], 3.85 ; 95%[CI], (0.9–15), as shown in Fig. 3(a). In the same context, ferritin concentration was recorded only in 14 patients between days 70-100 post allo-HCT. Median
ferritin level in this group was 2420 ng/mL (417 to 6362), at a mean number of 10.3 units per patient transfused in these cases (0 to 26). Meanwhile, the median initial ferritin level in this group was 943.4 (98 to 1850). Thus, we can conclude that high ferritin levels at the 3rd month post-HCT in these cases may simply reflect an iron overload caused by multiple transfusions (1 RBC unit contains 200 to 250 mg Fe), as shown in the Fig. 3a and 3b.

**Fig. 3 (a).** Linear correlation between the increased ferritin concentration pre-HCT and the number of RBC units transfused over 100 days post-HCT. (b) Steadily increased ferritin levels in group of patients (n=14) in whom ferritin amounts were recorded in the third month after HCT, median number of RBC units transfused in these cases was 10.3 units /patient (range, 0-26).

**Early post-transplant mortality**
Fifteen patients died during 100 days: 12 (23%) in HF, and 3 (8%) in LF group, without any significant difference (P>0.05). Significant difference in the mortality which occurred in pre- and post-engraftment was observed: 5 fatal outcomes (9.4%) were recorded only in HF group during the pre-engraftment period (P=0.003); resp., 8 cases (15.1%) and one case (2.6%) in HF and LF during 2nd month of post-engraftment (P=0.02). Treatment-related mortality (TRM) was observed in 7 cases, five of them (9 %), in HF, and two (5 %), in LF group (P>0.05). Hence, we did not find any relationship between the ferritin concentrations (at the cutoff level of 500 ng/mL), and mortality until the D+100. However, on the basis of ROC analysis, we assumed the general median to be the cutoff value (>773 ng/mL) for ferritin, and revealed a statistical difference for the mortality by D+100, i.e., 10 cases (27.7%) in group with high ferritin (≥773), and 5 lethal cases (9%) in the low-ferritin group (<773 ng/mL), P=0.02.

**Day 100 cumulative survival and disease-free survival**
With the cutoff ferritin concentration at 500 ng/mL (mean value of the sample), a significant statistical difference between two groups was not observed in the D100 cumulative survival and DFS: 77% and 62% in group 1 (ferritin ≥500) vs 89% and 76% in group2 (ferritin<500), respectively, (P > 0.05).

However, when we considered serum ferritin cutoff value of >773 ng/mL (the group median level), a significant statistical difference was observed. The D100 cumulative survival was 91% in group (F<773), vs 74% in HF group (P=0.04). D100 disease-free survival was 79% in group (F<773), versus 58% in group with high ferritin (F≥773), P=0.019. Hence, the pre-HSCT ferritin concentration at the over-median levels may be associated with lower OS and DFS, and could be considered as a risk factor (Fig. 4).

**Fig. 4 Kaplan-Meier curves: D+100 cumulative survival and DFS in two groups at ferritin cutoff value of ≥ 773 ng/mL.**
Discussion

The main objective of present study was to assess a predictive role of pre-allo-HCT ferritin concentrations, as a surrogate marker of iron overload in early transplant-related complications and outcome. The 500-ng/mL cutoff for serum ferritin concentration is less than in most previously reported series [3,8]. Our results suggest that a relatively mild iron overload in HCT recipients may also have toxic consequences. We did observe that high initial ferritin was significantly associated with increasing incidence of febrile neutropenia and bacterial infectious episodes, incidence of pneumonia and increased numbers of RBC units transfused post-HCT. Moreover, at an adjusted cutoff levels of ferritin (≥773 ng/mL), we noted significant associations between the increased pre-HCT ferritin concentration and poor overall survival, disease-free survival and higher transplant-related mortality. An association between increased pre-HCT ferritin level and active infections, especially, pre-existing pulmonary aspergillosis, was statistically significant. Other common complications, including mucositis, acute GvHD and CMV infection, did not demonstrate significant associations with ferritin contents. Due to small number of VOD cases, we could not find significant relationship with increasing ferritin.

Iron overload is known to be associated with increased susceptibility to different infections. Iron deprivation was found to be the key factor in the antimicrobial host defense. E.g., Pullarkat et al. [22] showed in a group of 190 patients with hematological malignancies that developing severe infectious complications were significantly higher in the high-ferritin category (OR=1.99, Wald test P=0.032). In contrast, Sucak et al. [24] showed no significant effect of pre-HCT iron status on bacteremia was observed (P>0.05). In our study, we have found that elevated pre transplant ferritin (≥500 ng/mL) was associated with increasing number of febrile neutropenia episodes (P=0.005), bacterial infections (P=0.009). That may reflect a role of IO in severe immune defect and predisposition to recurrent bacterial infections. Therefore, high ferritin level, as a marker of general IO, seems to be a sufficient cofactor in severe transplant-associated infections.

Also, in accordance with recently published studies [26], we found a delayed engraftment and increased percentage of patients who required G-CSF stimulation in the HF group (P=0.005).

According to Sucak et al. [24] the pre-HSCT high ferritin concentration correlated with pneumonia in allogeneic HCT recipients, thus being consistent with our results, where increased ferritin level (≥500) pre-HSCT proved to be associated with increasing pneumonia incidence (P = 0.04). Interestingly, the cases of isolated bacterial pneumonia were also frequent in the group with high ferritin levels (≥500 ng/mL) constituting 35.29% from causes of pneumonia in this group and this also confirms negative impact of iron overload in immunity, also as known bacteria need iron in their life cycle.

Some authors suggest a relationship between the pre-transplant ferritin levels and risk of invasive fungal infections (IFI) [2]. In contrast, other studies show that elevated serum fer-}

There are conflicting results for relationship between acute GvHD and IO, while some studies suggest that the incidence of aGvHD was still associated with ferritin levels ≥1000 ng/mL [22]. Another study has shown that ferritin levels over 1910 ng/mL correlate with a significantly lower incidence of acute GvHD, as well as limited and extensive chronic GvHD [18], thus supporting a hypothesis on suppressive effects of iron excess upon adaptive immune responses [6]. In our cohort, there was no correlation between a GvHD and elevated ferritin concentration pre-allo-HCT (P>0.05), but it was noted that there is a tendency for the occurrence of severe forms aGvHD III-IV, including the form of hepatic in the high-ferritin group, thus being in favor of a theory that hepatic iron overload may simulate or worsen hepatic aGvHD, since 90% of excessive iron is stored in the liver.

Several previous studies showed that elevated pre allo-HCT serum ferritin was an independent risk factor for SOS [20]. In our observation only 4 (4.3%) cases of VOD were diagnosed, with initial median ferritin level of 1704.3 ng/mL (112-4247). Low number of the VOD cases may be due to use of RIC and non-MAC conditioning regimens, and the use of heparin prophylaxis, thus making it impossible to perform valid statistical evaluation. Because of the small VOD incidence no significant statistical difference between the two groups was observed (P > 0.05).

We also observed that the patients with higher pre allo-HSCT ferritin levels required more blood transfusions than those in LF group. This may be attributed to presence of anti-RBC antibodies arising in heavily transfused patients [8] and to increasing incidence of febrile neutropenia and bacterial infections. Under the inflammatory conditions, hepcidin is secreted as a defensive mechanism, thus causing inhibition of iron release from its stores, thus preventing iron uptake for normal hematopoiesis and leading to slower recovery of erythroid lineage after HCT [2].

A number of previous studies, which used an indirect indicator of iron excess (serum ferritin) have found an association between the ferritin amounts and post-transplant survival using quite different threshold ferritin levels: F≥3000 [3]; F≥2515 [4]; F≥1910 [18]; F≥1000 [16]; F≥599 [13]; F≥500 [24]. Moreover, a negative impact of elevated ferritin proved to be associated with reduced overall and disease-free survival. However, when the pre-transplant IO was measured with MRI, such differences were not observed. E.g., Trottier et al. [27] did not find any association between pre-transplant iron excess defined by R2-MRI measured LIC and OS, NRM, relapse rate or GVHD. Similar results have been reported by Armand et al [4]. In our study, we observed significant correlation between pre allo-HCT ferritin >773 ng/mL and increased mortality, reduced OS and DFS at the end of 100 days post HSCT.
In conclusion, in accordance with previous findings, we observed increased incidence of infectious complications and adverse impact on engraftment rates. Serum ferritin may be considered the easiest way to estimate IO, being the most widely used method. Since serum ferritin is an acute phase reactant, its elevation may simply mirror inflammatory conditions, including an advanced disease phase that is shown to influence the outcomes in hematologic patients receiving allo-HSCT. The issue, whether high iron burden contributes directly to the poor outcome, or serum ferritin levels act as a surrogate marker for patient prognosis, requires further evaluation in prospective multicenter studies. Further studies using MRI assessment of tissue iron burden at various phases of HSCT, along with drawing appropriate correlations with clinical outcomes will be necessary in order to fully define the role of free iron in the patients undergoing HSCT.

Conflict of interest

None declared

References


